Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04674813 · ClinicalTrials.gov registry record · Phase 1
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
NCT04674813: Completed Phase 1 study, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
NCT04674813 is a Phase 1 study that has completed, run by Juno Therapeutics, a Subsidiary of Celgene. The registered enrollment target is 130 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (117% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04674813, a Phase 1 study, has completed, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Bendamustine
- DRUG CC-95266
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2025-12-22 |
| Phase | Phase 1 |
What the finished NCT04674813 record still lists
NCT04674813 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (117% higher).
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04674813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04674813 about?
NCT04674813 is a clinical study titled "A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma". The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).
What is the current status of trial NCT04674813?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2021-02-24. Estimated completion is 2025-12-22.
What interventions are being tested in trial NCT04674813?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Bendamustine (DRUG), CC-95266 (DRUG).
Who is sponsoring clinical trial NCT04674813?
This trial is sponsored by Juno Therapeutics, a Subsidiary of Celgene, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04674813's enrollment target sits among peer trials
130 439th of 2000 higher than 1,550 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI